Search Results - "Barrio, Andrea V."

Reconstruction in Women with T4 Breast Cancer after Neoadjuvant Chemotherapy: When Is It Safe? by Pawloski, Kate R., Barrio, Andrea V., Gemignani, Mary L., Sevilimedu, Varadan, Le, Tiana, Dayan, Joseph, Morrow, Monica, Tadros, Audree B.

“…Despite limited evidence regarding its safety, immediate reconstruction (IR) is increasingly offered to women with T4 breast cancer. We compared outcomes after…”
Get full text

Clinicopathologic features and long-term outcomes of 293 phyllodes tumors of the breast by Barrio, Andrea V, Clark, Bradly D, Goldberg, Jessica I, Hoque, Laura W, Bernik, Stephanie F, Flynn, Laurie W, Susnik, Barbara, Giri, Dilip, Polo, Kristen, Patil, Sujata, Van Zee, Kimberly J

“…Phyllodes tumors (PT) are rare fibroepithelial neoplasms of the breast with unpredictable behavior. We reviewed our single institution experience with PT over…”
Get full text

Pathologic complete response after neoadjuvant systemic therapy for breast cancer in BRCA mutation carriers and noncarriers by Myers, Sara P., Sevilimedu, Varadan, Barrio, Andrea V., Tadros, Audree B., Mamtani, Anita, Robson, Mark E., Morrow, Monica, Lee, Minna K.

“…BRCA1 and BRCA2 pathogenic variant carriers develop breast cancers with distinct pathological characteristics and mutational signatures that may result in…”
Get full text

Incidence of brain metastases in patients with early HER2-positive breast cancer receiving neoadjuvant chemotherapy with trastuzumab and pertuzumab by Ferraro, Emanuela, Singh, Jasmeet, Patil, Sujata, Razavi, Pedram, Modi, Shanu, Chandarlapaty, Sarat, Barrio, Andrea V., Malani, Rachna, Mellinghoff, Ingo K., Boire, Adrienne, Wen, Hannah Y., Brogi, Edi, Seidman, Andrew D., Norton, Larry, Robson, Mark E., Dang, Chau T.

“…The addition of pertuzumab (P) to trastuzumab (H) and neoadjuvant chemotherapy (NAC) has decreased the risk of distant recurrence in early stage HER2-positive…”
Get full text

Fine-needle aspiration cytology in the evaluation of patients with radiographically occult, palpable breast abnormalities by Ajkay, Nicolas, MD, Bloomquist, Erica V., MD, Martin, Robert C.G., MD, PhD, Frazier, Thomas G., MD, Barrio, Andrea V., MD, FACS

“…Background Patients who present with occult, palpable breast abnormalities on radiographs represent a diagnostic challenge. We hypothesized that fine-needle…”
Get full text

Social Work's Role in Bridging Breast Cancer Care Gaps-Reply by Barrio, Andrea V, Morrow, Monica, Mehrara, Babak J

Get more information

How Often Does Modern Neoadjuvant Chemotherapy Downstage Patients to Breast-Conserving Surgery? by Petruolo, Oriana, Sevilimedu, Varadan, Montagna, Giacomo, Le, Tiana, Morrow, Monica, Barrio, Andrea V.

“…Background Neoadjuvant chemotherapy (NAC) has been proven to increase breast-conserving surgery (BCS) rates, but data are limited on conversion rates from…”
Get full text

Selecting Node-Positive Patients for Axillary Downstaging with Neoadjuvant Chemotherapy by Montagna, Giacomo, Mamtani, Anita, Knezevic, Andrea, Brogi, Edi, Barrio, Andrea V., Morrow, Monica

“…Background Axillary lymph node dissection (ALND) can be avoided in node-positive patients who receive neoadjuvant chemotherapy (NAC) if three or more negative…”
Get full text

Managing the Morbidity: Individualizing Risk Assessment, Diagnosis, and Treatment Options for Upper Extremity Lymphedema by Montagna, Giacomo, Barrio, Andrea V

Get full text

Is Nodal Clipping Beneficial for Node-Positive Breast Cancer Patients Receiving Neoadjuvant Chemotherapy? by Montagna, Giacomo, Lee, Minna K., Sevilimedu, Varadan, Barrio, Andrea V., Morrow, Monica

“…Background In cN1 patients rendered cN0 with neoadjuvant chemotherapy, the false-negative rate of sentinel lymph node biopsy (SLNB) is < 10% when ≥ 3 sentinel…”
Get full text

ASO Author Reflections: Avoiding Mastectomy: The Benefit of Neoadjuvant Chemotherapy for Large Unifocal Breast Tumors by Petruolo, Oriana, Barrio, Andrea V.

Get full text

How Often Does Neoadjuvant Chemotherapy Avoid Axillary Dissection in Patients With Histologically Confirmed Nodal Metastases? Results of a Prospective Study by Mamtani, Anita, Barrio, Andrea V., King, Tari A., Van Zee, Kimberly J., Plitas, George, Pilewskie, Melissa, El-Tamer, Mahmoud, Gemignani, Mary L., Heerdt, Alexandra S., Sclafani, Lisa M., Sacchini, Virgilio, Cody, Hiram S., Patil, Sujata, Morrow, Monica

“…Background In breast cancer patients with nodal metastases at presentation, false-negative rates lower than 10 % have been demonstrated for sentinel node…”
Get full text

Controversies in the Treatment of Ductal Carcinoma in Situ by Barrio, Andrea V, Van Zee, Kimberly J

“…Ductal carcinoma in situ (DCIS) accounts for 20% of all newly diagnosed breast cancers. Mastectomy was once the gold standard for the treatment of DCIS;…”
Get full text

ASO Author Reflections: To Dissect or Not to Dissect—The Clinical Implications of Microscopic Extracapsular Extension in the Sentinel Node by Barrio, Andrea V., Morrow, Monica

Get full text

ASO Author Reflections: Is It Worth the Risk? The Benefit of Neoadjuvant Chemotherapy in Elderly Patients with Breast Cancer by Williams, Austin D., Barrio, Andrea V.

Get full text

Is local recurrence higher among patients who downstage to breast conservation after neoadjuvant chemotherapy? by Mamtani, Anita, Sevilimedu, Varadan, Le, Tiana, Morrow, Monica, Barrio, Andrea V.

“…Background In early studies, local recurrence (LR) rates were higher after neoadjuvant chemotherapy (NAC) in comparison with upfront surgery. Modern outcomes…”
Get full text

ASO Author Reflections: Acute or Chronic? The Effect of Axillary Lymph Node Dissection on Arm Symptoms and Quality of Life Over Time by Zhang, Jennifer Q., Barrio, Andrea V.

Get full text

A Prospective Validation Study of Bioimpedance with Volume Displacement in Early-Stage Breast Cancer Patients at Risk for Lymphedema by Barrio, Andrea V., Eaton, Anne, Frazier, Thomas G.

“…Background Although volume displacement (VD) is considered the gold standard for diagnosing breast cancer-related lymphedema, it is inconvenient. We compared…”
Get full text

The Optimal Treatment Plan to Avoid Axillary Lymph Node Dissection in Early-Stage Breast Cancer Patients Differs by Surgical Strategy and Tumor Subtype by Pilewskie, Melissa, Zabor, Emily C., Mamtani, Anita, Barrio, Andrea V., Stempel, Michelle, Morrow, Monica

“…Background Strategies to reduce the likelihood of axillary lymph node dissection (ALND) include application of Z0011 or use of neoadjuvant chemotherapy (NAC)…”
Get full text

Quality of Life After Axillary Lymph Node Dissection Among Racial and Ethnic Minority Women by Heller, Danielle R, Axelrod, Bayley, Sevilimedu, Varadan, Morrow, Monica, Mehrara, Babak J, Barrio, Andrea V

“…Higher lymphedema rates after axillary lymph node dissection (ALND) have been found in Black and Hispanic women; however, there is poor correlation between…”
Get more information